Marshall Wace, LLP Ventyx Biosciences, Inc. Put Options Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VTYX
# of Institutions
119Shares Held
49.1MCall Options Held
70.4KPut Options Held
51.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.9MShares$15.5 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$12.5 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY4.54MShares$11.9 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$8.32 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$8.15 Million0.4% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $149M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...